Quidel

QuidelOrtho reported total revenue of $620m for Q1 2026 (−13% organic) and an adjusted diluted loss of $0.04 per share, missing analysts' expectations. Point-of-care revenue declined 34.6% and respiratory sales collapsed 43.6%, resulting in an unfavorable product mix and a 630-basis-point drop in adjusted gross margin to 43.8%. Adjusted EBITDA fell to $109m, free cash flow was negative (−$67m), and net debt stands at $2.6bn (~4.8x adjusted EBITDA). Management cut the full-year guidance to $2.70–2.75bn in revenue and expects adjusted EBITDA of $615–630m and adjusted EPS of $1.80–2.00; strategic actions such as the acquisition of LEX Diagnostics are intended to drive growth and efficiency. » More on de.investing.com

Quidel Corporation shares hit a 52-week low of $14.43 and are currently trading at $14.38, with a market capitalization of around $1 billion. The stock is down roughly 47% over the past 12 months, but analysts have price targets between $25 and $50 and forecast EPS of $2.16 for fiscal 2026. Investors are watching the quarterly report on May 13, after QuidelOrtho recently reported mixed Q4 results (adjusted EPS $0.46 vs. $0.51 expected, revenue $724 million). » More on de.investing.com

Quidel’s stock is trading around $17.11 near its 52-week low and is more than 50% below last year’s price. An InvestingPro analysis values the fair price at $19.75, indicating a possible undervaluation despite a debt load of $2.85 billion. Analysts expect earnings of $2.16 per share for 2026, and QuidelOrtho reported adjusted EPS of $0.46 in Q4/2025 (below expectations) on revenue of $724 million (slightly above expectations). » More on de.investing.com